E. A. Espiner, M.D., M.R.A.C.P., P. I. Jagger, M.D., J. R. Tucci, M.D., and D. P. Lauler, M.D. In nine separate studies on four patients with severe pitting edema ...

Currently, patients with HFpEF have high risk of morbidity and mortality, but there is no effective measure for evaluating the prognosis. Studies have found that a variety of ways can lead to the ...

A drug that has been used to slow progression of kidney and cardiovascular disease in people with type 2 diabetes may also help people with chronic kidney disease who do not have diabetes, according ...

Higher serum aldosterone levels among patients with chronic kidney disease (CKD) are independently associated with an increased risk for CKD progression and end-stage kidney disease (ESKD) regardless ...

Please provide your email address to receive an email when new articles are posted on . Aldosterone is associated with an increased risk of chronic kidney disease progression and the development of ...

In a phase 2 trial, an investigational drug that inhibits aldosterone synthase significantly lowered albuminuria in patients with or without type 2 diabetes. PHILADELPHIA—A novel selective aldosterone ...

Please provide your email address to receive an email when new articles are posted on . Once-daily lorundrostat, an aldosterone synthase inhibitor, significantly decreased automated office systolic BP ...

Current treatment options for primary aldosteronism are limited to surgery or mineralocorticoid receptor antagonists when surgery isn't an option. In a phase IIa trial, baxdrostat resolved or reduced ...

The coronavirus disease 2019 (COVID-19) pandemic caused millions of deaths throughout the world, which has provoked intense research into the pathogenetic mechanism behind this disease. A new study ...

PHILADELPHIA -- An oral investigational aldosterone synthase inhibitor (ASI) cut albuminuria by nearly 40% in people in chronic kidney disease (CKD) in a phase II trial. The 10-mg dose of ASI BI ...